Mars or Venus — Is Sex a Risk Factor for Recurrent Venous Thromboembolism?

2004 ◽  
Vol 350 (25) ◽  
pp. 2614-2616 ◽  
Author(s):  
C. Gregory Elliott ◽  
Lewis J. Rubin
Keyword(s):  
Risk Factor ◽  
Venous Thromboembolism ◽  
Recurrent Venous Thromboembolism

Risk of Pregnancy-Associated Venous Thromboembolism in Women with a History of Prior Thrombosis.

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 1493-1493 ◽  
Author(s):  
Andrea Gerhardt ◽  
Rudiger E. Scharf ◽  
Rainer B. Zotz
Keyword(s):  
Risk Factor ◽  
Venous Thromboembolism ◽  
Gene Mutation ◽  
Factor V Leiden ◽  
Prothrombin G20210a ◽  
Factor V ◽  
Previous Episode ◽  
Recurrent Venous Thromboembolism ◽  
History Of ◽  
Heparin Prophylaxis

Abstract Background: Previous estimates of the rate of recurrent venous thromboembolism (VTE) during pregnancy in women with a history of VTE have vary between 0 and 13%. Therefore, the decision to administer or withhold heparin - especially in the antepartum period - has been discussed controversial. In a recent study by Brill-Edwards et al. (N Engl J Med2000;343:1439–44), no recurrences of VTE occurred in women (n=44) who had a previous episode of thrombosis that was associated with a temporary risk factor and who also had no evidence of thrombophilia. Based on these results, antepartum heparin prophylaxis is not routinely recommended in women without thrombophilia whose previous episode of thrombosis was associated with a temporary risk factor (ACCP guidelines 2004). The objective of our study was to evaluate the risk of recurrent pregnancy-associated thrombosis in women with a history of VTE. Materials and Methods: We retrospectively studied 198 women with at least one pregnancy (275 pregnancies in total) after a one previous episode of VTE. Sixty-three women (81 pregnancies) were excluded from the analysis because of antepartum heparin prophylaxis. Results: In the subgroup of women without heparin prophylaxis (n=135), 15 (7.7%) thromboembolic events occurred antepartum in 194 pregnancies. Further subgroup analysis, stratified for the nature of first VTE, gave the following number of antepartum VTE per number of pregnancies: 2 VTE/19 pregnancies (10.5%) in 14 women (first VTE: immobilization), 4 VTE/33 pregnancies (12.1%) in 24 women (first VTE: surgery), 5 VTE/69 pregnancies (7.2%) in 46 women (first VTE: oral contraception), 2 VTE/58 pregnancies (3.4%) in 40 women (first VTE: pregnancy), 2 VTE/15 pregnancies (13%) in 11 women (first VTE: idiopathic). Nine of the 15 women with VTE (7/13 women with first VTE triggered by temporary risk factor; 2/2 women with first idiopathic VTE) had a heterozygous factor V Leiden G1691A or prothrombin G20210A gene mutation. In the postpartum period, 16 VTE in 194 pregnancies occurred after live birth in the 135 women without heparin prophylaxis. Nine of these 16 women had a heterozygous FVL or prothrombin G20210A gene mutation. In Conclusion, the risk of recurrent antepartum VTE was similar in women with and without factor V Leiden G1691A or the prothrombin G20210A gene mutation and did not differ between women with first VTE triggered by a transient risk factor or an idiopathic first VTE. In addition to recommended postpartum heparin prophylaxis, our data support the need for a routine antepartum prophylaxis in women without thrombophilia whose previous episode of thrombosis was associated with a temporary risk factor.

Inflammatory Bowel Disease Is a Risk Factor for Recurrent Venous Thromboembolism

2010 ◽  
Vol 139 (3) ◽  
pp. 779-787.e1 ◽  
Author(s):  
Gottfried Novacek ◽  
Ansgar Weltermann ◽  
Anna Sobala ◽  
Herbert Tilg ◽  
Wolfgang Petritsch ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Risk Factor ◽  
Venous Thromboembolism ◽  
Bowel Disease ◽  
Recurrent Venous Thromboembolism ◽  
Inflammatory Bowel

Non-OO blood type influences the risk of recurrent venous thromboembolism

2013 ◽  
Vol 110 (12) ◽  
pp. 1172-1179 ◽  
Author(s):  
Esteban Gándara ◽  
Michael J. Kovacs ◽  
Susan R. Kahn ◽  
Philip S. Wells ◽  
David A. Anderson ◽  
...  
Keyword(s):  
Risk Factor ◽  
Venous Thromboembolism ◽  
Anticoagulant Therapy ◽  
Oral Anticoagulation ◽  
Blood Type ◽  
Increased Risk ◽  
Recurrent Venous Thromboembolism ◽  
Abo Blood Type ◽  
Recurrent Vte

SummaryThe role of ABO blood type as a risk factor for recurrent venous thromboembolism (VTE) in patients with a first unprovoked VTE who complete oral anticoagulation therapy is unknown. The aim of this study was to determine if non-OO blood type is a risk factor for recurrent VTE in patients with a first unprovoked VTE who completed 5–7 months of anticoagulant therapy. In an ongoing cohort study of patients with unprovoked VTE who discontinued oral anticoagulation after 5–7 months of therapy, six single nucleotide polymorphisms sites were tested to determine ABO blood type using banked DNA. The main outcome was objectively proven recurrent VTE. Mean follow-up for the cohort was 4.19 years (SD 2.16). During 1,553 patient-years of follow-up, 101 events occurred in 380 non-OO patients (6.5 events per 100 patient years; 95% CI 5.3–7.7) compared to 14 events during 560 patient years of follow-up in 129 OO patients (2.5 per 100 patient years; 95% CI 1.2–3.7), the adjusted hazard ratio was 1.98 (1.2–3.8). In conclusion, non-OO blood type is associated with a statistically significant and clinically relevant increased risk of recurrent VTE following discontinuation of anticoagulant therapy for a first episode of unprovoked VTE.

scholarly journals Circumstances of provoked recurrent venous thromboembolism: the Austrian study on recurrent venous thromboembolism

2019 ◽  
Vol 49 (4) ◽  
pp. 505-510
Author(s):  
Hannah C. Puhr ◽  
Lisbeth Eischer ◽  
Hana Šinkovec ◽  
Ludwig Traby ◽  
Paul A. Kyrle ◽  
...  
Keyword(s):  
Risk Factor ◽  
Venous Thromboembolism ◽  
Oral Anticoagulants ◽  
Recurrence Risk ◽  
Major Surgery ◽  
Vein Thrombosis ◽  
Recurrent Venous Thromboembolism ◽  
Risk Condition ◽  
Minor Surgery ◽  
A Minor

Abstract Patients with unprovoked deep-vein thrombosis (DVT) of the leg or pulmonary embolism (PE) have a high recurrence risk. How often these recurrences are provoked by a temporary risk condition is unknown. In a cohort of patients with unprovoked venous thromboembolism (VTE), we evaluated the clinical circumstances of recurrence. We studied patients with DVT of the leg and/or PE. End point was recurrence of objectively verified symptomatic VTE. Provoked recurrence was defined according to guidance criteria. 1188 patients were followed for a median of 8.9 years after withdrawal of oral anticoagulants. 312 patients had recurrent VTE, which was provoked in 42 (13%). Recurrence was related to a major risk factor in 19, to a minor risk factor in 22, and to a persistent risk factor in one patient(s). 14 recurrences occurred after major surgery and 5 during hospitalization. Ten recurrences occurred after minor surgery, eight after trauma and three during female hormone intake. Four recurrences occurred during heparin prophylaxis. The incidence of provoked VTE recurrence appears to be low. VTE can recur when prevention is stopped or even during thromboprophylaxis. Surgery and trauma are frequent risk factors.

scholarly journals Depressive Symptoms as a Novel Risk Factor for Recurrent Venous Thromboembolism: A Longitudinal Observational Study in Patients Referred for Thrombophilia Investigation

PLoS ONE ◽  
2015 ◽  
Vol 10 (5) ◽  
pp. e0125858 ◽  
Author(s):  
Roland von Känel ◽  
Angelina Margani ◽  
Stefanie Stauber ◽  
Fiorenza A. Meyer ◽  
Franziska Demarmels Biasiutti ◽  
...  
Keyword(s):  
Risk Factor ◽  
Depressive Symptoms ◽  
Venous Thromboembolism ◽  
Observational Study ◽  
Longitudinal Observational Study ◽  
Recurrent Venous Thromboembolism

Anti-prothrombin antibodies as a potential risk factor of recurrent venous thromboembolism

2004 ◽  
Vol 91 (02) ◽  
pp. 255-258 ◽  
Author(s):  
Ezio Zanon ◽  
Graziella Saggiorato ◽  
Roberto Ramon ◽  
Antonio Girolami ◽  
Antonio Pagnan ◽  
...  
Keyword(s):  
Risk Factor ◽  
Venous Thromboembolism ◽  
Antiphospholipid Antibodies ◽  
Potential Role ◽  
Clinical Presentation ◽  
Multivariate Logistic Regression Analysis ◽  
Entire Cohort ◽  
Recurrent Venous Thromboembolism ◽  
History Of

SummaryThe role of antiprothrombin (aPT) antibodies in the development of venous thromboembolism (VTE) is still uncertain. The aim of this study was to evaluate the potential role of aPT antibodies in the development of recurrent thromboembolism. Out of 236 consecutive symptomatic patients with an episode of acute VTE, antiphospholipid antibodies were found in 85 (36.0%), of whom 24 were carriers of aPT antibodies (10.2% of the entire cohort). A history of previous thromboembolism was identified in 56 patients (23.7%). The prevalence of previous thromboembolism was significantly higher in carriers than in non-carriers of antiphospholipid antibodies (OR=2.4; 95% CI, 1.3 to 4.4). Of the 24 patients with aPT antibodies, 12 had a history of previous thromboembolism. In a multivariate logistic regression analysis, in which the other categories of antiphospholipid antibodies were taken into account, as well as the patient’s age, sex, and the modality of clinical presentation, it was found that the presence of aPT antibodies was significantly associated with the prevalence of prior thromboembolism (OR=3.3; 95% CI, 1.3 to 8.6). Since aPT antibodies are more commonly identifiable in patients with multiple thrombotic episodes, they are a likely risk factor for recurrent thromboembolism.

scholarly journals Risk of recurrent venous thromboembolism according to baseline risk factor profiles

2018 ◽  
Vol 2 (7) ◽  
pp. 788-796 ◽  
Author(s):  
Martin H. Prins ◽  
Anthonie W. A. Lensing ◽  
Paolo Prandoni ◽  
Philip S. Wells ◽  
Peter Verhamme ◽  
...  
Keyword(s):  
Risk Factors ◽  
Risk Factor ◽  
Venous Thromboembolism ◽  
Baseline Risk ◽  
Risk Of Recurrence ◽  
Baseline Risk Factor ◽  
Key Points ◽  
Recurrent Venous Thromboembolism

Key Points The risk of recurrence in patients with VTE provoked by minor transient or persistent risk factors is uncertain. The risk of recurrence with VTE provoked by minor transient or persistent risk factors is similar to that with unprovoked VTE.

Sign in / Sign up

Export Citation Format

Share Document